Our aspiration is to transform the biopharmaceutical landscape by enabling best-in-class oral biological therapeutics.
Applied Molecular Transport is advancing its pipeline of oral and targeted biological and peptide therapeutics to treat autoimmune, inflammatory and metabolic diseases. Our overriding patient-centric goal is to enhance therapeutic outcomes and improve drug safety profiles of established and novel biopharmaceuticals.
Our platform technology, TRANSINT, enables the trafficking of peptides and proteins across epithelial barriers (with a focus on the intestinal epithelium) as well as receptor-mediated, targeted presentation of these therapeutic cargos to cells of the immune system for immune-suppressive or immune-stimulatory activity.
By eliminating the need for injections for our therapeutic products, we expect this approach to provide additional treatment outcomes benefits from improved patient convenience and drug regimen adherence.
We are building integrated capabilities and a world-class organization that is passionate, savvy and experienced in the science, engineering and business of biopharmaceutical development.
Copyright © APPLIED MOLECULAR TRANSPORT, LLC 2016. All rights reserved.